KLK3 and metastatic neoplasm: While this offers temporary cancer control, most patients ultimately develop castrate resistant prostate cancer (CRPC) with a rise in serum levels of prostate specific antigen (PSA), used as a marker of tumor growth, and continue to progress with metastatic disease [72].